Multiepitopic B- and T-cell responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine

Journal of Virology

Volumn 74, Issue 4, 2000, Pages 1694-1703

  Gahéry Ségard, Hanne ^a   Pialoux, Gilles ^b   Charmeteau, Bénédicte ^a   Sermet, Sandrine ^a   Poncelet, Hubert ^b   Raux, Maurice ^c   Tartar, Ré ^d   Lévy, Jean Paul ^a   Gras Masse, Helene ^e   Guillet, Jean gérard ^a  

^a INSTITUT COCHIN   (France)

^b INSTITUT PASTEUR   (France)

^c Clinical Sero Immunology Laboratory   (France)

^d INSTITUT PASTEUR DE LILLE   (France)

^e UNIV LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN G ANTIBODY; IMMUNOLOGICAL ADJUVANT; LIPOPEPTIDE; QS 21;

ARTICLE; CARBOXY TERMINAL SEQUENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG SAFETY; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; LYMPHOCYTE PROLIFERATION; NONHUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; VACCINATION;

AIDS VACCINES; AMINO ACID SEQUENCE; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CONSUMER PRODUCT SAFETY; EPITOPES, B-LYMPHOCYTE; EPITOPES, T-LYMPHOCYTE; GENE PRODUCTS, GAG; GENE PRODUCTS, NEF; HIV ANTIGENS; HIV ENVELOPE PROTEIN GP120; HIV-1; HUMANS; INTERFERON TYPE II; LIPOPROTEINS; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 0342647378     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.74.4.1694-1703.2000     Document Type: Article

References (33)

1. BenMohamed, L., H. Gras-Masse, A. Tartar, P. Daubersies, K. Brahimi, M. Bossus, A. Thomas, and P. Druilhe. 1997. Lipopeptide immunization without adjuvant induces potent and long-lasting B, T helper, and cytotoxic T lymphocyte responses against a malaria liver stage antigen in mice and chimpanzees. Eur. J. Immunol. 27:1242-1253.
2. Clements-Mann, M. L., K. Weinhold, T. J. Matthews, B. S. Graham, G. J. Gorse, M. C. Keefer, M. J. McElrath, R. H. Hsieh, J. Mestecky, S. Zolla-Pazner, J. Mascola, D. Schwartz, R. Siliciano, L. Corey, P. F. Wright, R. Belshe, R. Dolin, S. Jackson, S. Xu, P. Fast, M. C. Walker, D. Stablein, J. L. Excler, J. Tartaglia, E. Paoletti, and A. v. e. Group. 1998. Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1 MN gp120, HIV-1 SF2 recombinant gp120, or both vaccines in seronegative adults. J. Infect. Dis. 177:1230-1246.
3. Connan, F., F. Hlavac, J. Hoebeke, J. G. Guillet, and J. Choppin. 1994. A simple assay for detection of peptides promoting the assembly of HLA class I molecules. Eur. J. Immunol. 24:777-780.
4. Connor, R., B. Korber, B. Graham, B. Hahn, D. D. Ho, B. Walker, A. Neumann, S. Vermund, J. Mestecky, S. Jackson, E. Fenamore, Y. Cao, F. Gao, S. Kalams, K. Kunstman, D. McDonald, N. McWilliams, A. Trkola, J. Moore, and S. Woonsky. 1998. Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines. J. Virol. 72:1552-1576.
5. Couillin, I., B. Culmann-Penciolelli, E. Gomard, J. Choppin, J. P. Levy, J. G. Guillet, and S. Saragosti. 1994. Impaired CTL recognition due to genetic variations in the main immunogenic region of the HIV-1 Nef protein. J. Exp. Med. 180:1129-1134.
6. + T-cell effector activity in HIV primary infection. J. Clin. Investig. 104:1431-1439.
7. + responses in HIV type 1-infected patients: comparison with anti-Epstein-Barr virus responses and changes during antiretroviral therapy. J. Virol. 73:7108-7116.
8. + cell suppressor factors and cytotoxic T lymphocytes during HIV infection. AIDS Res. Hum. Retroviruses 14:153-160.
9. Ferrari, G., W. Humphrey, M. McElrath, J. Excler, A. M. Duliege, M. L. Clements, L. C. Corey, D. P. Bolognesi, and K. J. Weinhold. 1997. Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers. Proc. Natl. Acad. Sci. USA 94:1396-1401.
10. Fujinaga, K., Q. Zhong, T. Nakaya, M. Kameoka, T. Meguro, K. Yamada, and K. Ikuta. 1995. Extracellular NEF protein regulates productive HIV-1 infection from latency. J. Immunol. 155:5289-5298.
11. Gahéry-Ségard, H., F. Farace, D. Godfrin, J. Gaston, R. Lengagne, P. Boulanger, and J.-G. Guillet. 1998. Immune response to recombinant capsid proteins of adenovirus in humans: anti-fiber and anti-penton base antibodies have a synergistic effect in neutralizing activity. J. Virol. 72:2388-2397.
12. + T lymphocytes from macaques immunized with live attenuated SIV. J. Virol. 72:6315-6324.
13. Graham, B., and P. Wright. 1995. Candidate AIDS vaccines. N. Engl. J. Med. 333:1331-1339.
14. Johnson, R. P., J. D. Lifson, S. C. Czajak, K. Stefano Cole, K. H. Manson, R. Glickman, J. Yang, D. C. Montefiori, R. Montelaro, M. S. Wyand, and R. C. Desrosiers. 1999. Highly attenuated vaccine strains of simian immunodeficiency virus protect against vaginal challenge: inverse relationship of degree of protection with level of attenuation. J. Virol. 73:4952-4961.
15. Klinguer, C., D. David, M. Kouach. J. M. Wieruszeski, A. Tartar, D. Marzin, J. P. Levy, and H. Gras-Masse. 1999. Characterization of a multi-lipopeptides mixture used as an HIV-1 vaccine candidate. Vaccine 18:259-267.
16. Koening, S., A. J. Conley, Y. A. Brewah, G. M. Jones, S. Leath, L. J. Boots, V. Davey, G. Pantaleo, J. F. Demarest, and C. Carter. 1915. Transfer of HIV-1 specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression. Nat. Med 1: 330-336.
17. Koup, R. A., J. T. Salfrit, Y. Cao, C. A. Andrews, G. McLeod, W. Borkowsky, C. Farthing, and D. D. Ho. 1994. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68:4650-4655.
18. Lalvani, B. A., R. Brookes, S. Hambleton, W. J. Britton, A. V. S. Hill, and A. J. McMichael. 1997. Rapid effector in CD8+ memory T cells. J. Exp. Med. 186:859-865.
19. Lanzavecchia, A. 1998. Immunology. Licence to kill. Nature 393:413-414.
20. Livingston, B. D., C. Crimi, H. Grey, G. Ishioka, F. V. Chisari, J. Fikes, H. Grey, R. W. Cbesnut, and A. Sette. 1997. The hepatitis B virus-specific CTL responses induced in humans by lipopeptide vaccination are comparable to those elicited by acute viral infection. J. Immunol. 159:1383-1392.
21. Mackewicz, C., E. Barker, G. Greco, G. Reyes-Teran, and J. Levy. 1997. Do heta-chemokines have clinical relevance in HIV infection? J. Clin. Investig. 100:921-930.
22. Martinon, F., H. Gras-Masse, C. Boutillon, A. Tartar, and J. P. Levy. 1992. Immunization of mice with lipopeptides bypasses the prerequisite for adjuvant: immune response of BALB/c mice to human immunodeficiency virus envelope glycoprotein. J. Immunol. 149:3416-3422.
23. Mortara, L., H. Gras-Masse, C. Rommens, A. Venet, J. G. Guillet, and I. Bourgault-Villada. 1999. Type 1 CD4+ T-cell help is required for induction of antipeptide multispecific cytotoxic T lymphocytes by a lipopeptidic vaccine in rhesus macaques. J. Virol. 73:4447-4451.
24. Mortara. L., F. Letourneur, H. Gras-Masse, A. Venet, J. G. Guillet, and I. Bourgault-Villada. 1998. Selection of virus variants and emergence of virus escape mutants after immunization with epitope vaccine. J. Virol. 72:1403-1410.
25. + T cells. J. Immunol. 153:5826-5837.
26. + T-helper and a T-killer cell. Nature 393:474-478.
27. + T lymphocytes induced by peptide immunization: an ex-vivo analysis. Int. Immunol. 10:1273-1279.
28. + T cell responses associated with control of viremia. Science 278:1447-1450.
29. Sauzet, J. P., B. Deprez, F. Martinon, J. G. Guillet, H. Gras-Masse, and E. Gomard. 1995. Long-lasting anti-viral cytotoxic T lymphocytes induced in vivo with chimeric-multirestricted lipopeptides. Vaccine 13:1339-1345.
30. Sauzet, J. P., H. Gras-Masse, J. G. Guillet, and E. Gomard. 1996. Influence of strong CD4 epitope on long-term virus-specific cytotoxic T cell responses induced in vivo with peptides. Int. Immunol. 8:457-465.
31. Sauzet, J. P., C. Moog, A. Krivine, F. Martinon, M. Bossus, H. Gras-Masse, A. Tartar, J. G. Guillet, and E. Gomard. 1998. Adjuvant is required when using Env lipopeptide construct to induce HIV type 1-specific neutralizing antibody responses in mice in vivo. AIDS Res. Hum. Retroviruses 14:901-909.
32. + lymphocytes. Science 283:857-860.
33. Vitiello, A., G. Ishioka, H. M. Grey, R. Rose, P. Farness, R. LaFond, L. Yuan, F. V. Chisari, J. Furze, R. Bartholomeuz, and R. Chesnut. 1995. Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans. J. Clin. Investig. 95:341-349.